Literature DB >> 18362898

Erythropoiesis-stimulating agents and other methods to enhance oxygen transport.

S Elliott1.   

Abstract

Oxygen is essential for life, and the body has developed an exquisite method to collect oxygen in the lungs and transport it to the tissues. Hb contained within red blood cells (RBCs), is the key oxygen-carrying component in blood, and levels of RBCs are tightly controlled according to demand for oxygen. The availability of oxygen plays a critical role in athletic performance, and agents that enhance oxygen delivery to tissues increase aerobic power. Early methods to increase oxygen delivery included training at altitude, and later, transfusion of packed RBCs. A breakthrough in understanding how RBC formation is controlled included the discovery of erythropoietin (Epo) and cloning of the EPO gene. Cloning of the EPO gene was followed by commercial development of recombinant human Epo (rHuEpo). Legitimate use of this and other agents that affect oxygen delivery is important in the treatment of anaemia (low Hb levels) in patients with chronic kidney disease or in cancer patients with chemotherapy-induced anaemia. However, competitive sports was affected by illicit use of rHuEpo to enhance performance. Testing methods for these agents resulted in a cat-and-mouse game, with testing labs attempting to detect the use of a drug or blood product to improve athletic performance (doping) and certain athletes developing methods to use the agents without being detected. This article examines the current methods to enhance aerobic performance and the methods to detect illicit use.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18362898      PMCID: PMC2439521          DOI: 10.1038/bjp.2008.89

Source DB:  PubMed          Journal:  Br J Pharmacol        ISSN: 0007-1188            Impact factor:   8.739


  160 in total

1.  Improvement of brain function in hemodialysis patients treated with erythropoietin.

Authors:  G Grimm; F Stockenhuber; B Schneeweiss; C Madl; J Zeitlhofer; B Schneider
Journal:  Kidney Int       Date:  1990-09       Impact factor: 10.612

2.  KDOQI Clinical Practice Guidelines and Clinical Practice Recommendations for Anemia in Chronic Kidney Disease.

Authors: 
Journal:  Am J Kidney Dis       Date:  2006-05       Impact factor: 8.860

3.  Treatment of sickle cell anemia with cobalt chloride.

Authors:  J WOLF; I J LEVY
Journal:  AMA Arch Intern Med       Date:  1954-03

4.  Peritubular cells are the site of erythropoietin synthesis in the murine hypoxic kidney.

Authors:  C Lacombe; J L Da Silva; P Bruneval; J G Fournier; F Wendling; N Casadevall; J P Camilleri; J Bariety; B Varet; P Tambourin
Journal:  J Clin Invest       Date:  1988-02       Impact factor: 14.808

5.  Erythropoietin: gene cloning, protein structure, and biological properties.

Authors:  J K Browne; A M Cohen; J C Egrie; P H Lai; F K Lin; T Strickland; E Watson; N Stebbing
Journal:  Cold Spring Harb Symp Quant Biol       Date:  1986

Review 6.  Assessment of risks in occupational cobalt exposures.

Authors:  G Nordberg
Journal:  Sci Total Environ       Date:  1994-06-30       Impact factor: 7.963

7.  Use of recombinant human erythropoietin for management of anemia in dogs and cats with renal failure.

Authors:  L D Cowgill; K M James; J K Levy; J K Browne; A Miller; R T Lobingier; J C Egrie
Journal:  J Am Vet Med Assoc       Date:  1998-02-15       Impact factor: 1.936

8.  The first human cell line-derived erythropoietin, epoetin-delta (Dynepo), in the management of anemia in patients with chronic kidney disease.

Authors:  K J Martin
Journal:  Clin Nephrol       Date:  2007-07       Impact factor: 0.975

9.  Low dose erythropoietin in maintenance haemodialysis: improvement in quality of life and reduction in true cost of haemodialysis.

Authors:  D C Harris; J R Chapman; J H Stewart; S Lawrence; S D Roger
Journal:  Aust N Z J Med       Date:  1991-10

10.  Desferrioxamine enhances the haemopoietic response to erythropoietin, but adverse events are common.

Authors:  S D Roger; J H Stewart; D C Harris
Journal:  Nephron       Date:  1991       Impact factor: 2.847

View more
  14 in total

Review 1.  The evolving science of detection of 'blood doping'.

Authors:  Carsten Lundby; Paul Robach; Bengt Saltin
Journal:  Br J Pharmacol       Date:  2012-03       Impact factor: 8.739

Review 2.  Performance-enhancing drugs.

Authors:  Christopher Dandoy; Rani S Gereige
Journal:  Pediatr Rev       Date:  2012-06

Review 3.  Drugs in sport: a scientist-athlete's perspective: from ambition to neurochemistry.

Authors:  M Spedding; C Spedding
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 4.  Performance-Enhancing Drug Use in Adolescence.

Authors:  Nicole D White; James Noeun
Journal:  Am J Lifestyle Med       Date:  2016-11-29

Review 5.  Adverse health consequences of performance-enhancing drugs: an Endocrine Society scientific statement.

Authors:  Harrison G Pope; Ruth I Wood; Alan Rogol; Fred Nyberg; Larry Bowers; Shalender Bhasin
Journal:  Endocr Rev       Date:  2013-12-17       Impact factor: 19.871

Review 6.  Erythropoietin.

Authors:  H Franklin Bunn
Journal:  Cold Spring Harb Perspect Med       Date:  2013-03-01       Impact factor: 6.915

7.  Drugs in sport.

Authors:  J C McGrath; D A Cowan
Journal:  Br J Pharmacol       Date:  2008-06       Impact factor: 8.739

Review 8.  Drug abuse in athletes.

Authors:  Claudia L Reardon; Shane Creado
Journal:  Subst Abuse Rehabil       Date:  2014-08-14

Review 9.  Drugs of abuse and the adolescent athlete.

Authors:  Alan D Rogol
Journal:  Ital J Pediatr       Date:  2010-02-18       Impact factor: 2.638

10.  Exogenous sphingosine-1-phosphate boosts acclimatization in rats exposed to acute hypobaric hypoxia: assessment of haematological and metabolic effects.

Authors:  Sonam Chawla; Babita Rahar; Mrinalini Singh; Anju Bansal; Deepika Saraswat; Shweta Saxena
Journal:  PLoS One       Date:  2014-06-02       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.